Overexpression of EPHA2 has been observed in multiple cancers and reported to be associated with poor prognosis. Here, we produced an afucosylated humanized anti-EPHA2 monoclonal antibody (mAb), DS8895a for cancer treatment. The antibody recognizes the extracellular juxtamembrane region of EPHA2 and therefore can bind to both full-length and truncated forms of EPHA2, which are anchored to cell membranes and recently reported to be produced by post-translational cleavage in tumors. DS-8895a exhibited markedly increased antibody dependent cellular cytotoxicity (ADCC) in vitro and also inhibited tumor growth in EPHA2-positive human breast cancer MDA-MB-231 and human gastric cancer SNU-16 xenograft mouse models. Moreover, DS-8895a in combination with cisplatin (CDDP) showed better efficacy than each of the monotherapies did in the human gastric cancer model. These results suggest that a novel antibody, DS-8895a has therapeutic potential against EPHA2-expressing tumors.
Introduction
EPHA2 is a type-I transmembrane receptor tyrosine kinase that belongs to the EPH receptor family, and its ligands are ephrin-A1 to A5. 1 EPHA2 overexpression has been observed in a wide variety of neoplasms such as gastric cancer, colorectal cancer, esophageal cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, prostate cancer, ovarian cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, renal cancer, brain tumors, head and neck cancer, and melanoma. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] EPHA2 is also associated with poor prognosis in cancers of the stomach, esophagus, lung, liver, ovary, endometrium, kidney, brain, and head and neck. 2, [4] [5] [6] 8, 10, [14] [15] [16] [17] EPHA2 expression is upregulated by the Ras-extracellular signalregulated kinase (ERK) signaling pathway, which promotes tumor growth and survival and is frequently activated by constitutive active mutations in molecules involved in the pathway or by constitutive signals from overexpressed growth factor receptors in aggressive tumors. 19, 20 Recently, it has been reported that membrane type-1 matrix metalloproteinase (MT1-MMP) on tumor cells cleaves EPHA2 at the extracellular domain and the resultant truncated and membrane-anchoring forms of EPHA2 promote oncogenic signaling. 21, 22 These findings suggest that tumor cells contain not only full-length but also truncated forms of EPHA2 on their cell surface, and the truncated forms of EPHA2 are important for EPHA2-targeting cancer therapy.
In the past 2 decades, several monoclonal antibodies (mAbs) that mediate antibody-dependent cellular cytotoxicity (ADCC) have been approved for cancer treatment, including conventional antibodies: rituximab (anti-CD20 mAb), trastuzumab (anti-ERBB2 mAb), and cetuximab (anti-EGFR mAb); and glycoengineered antibodies: mogamulizumab (afucosylated anti-CCR4 mAb) and obinutuzumab (afucosylated anti-CD20 mAb). [23] [24] [25] [26] ADCC is triggered by formation of the complex comprising antibody, its cell surface antigen on target cells, and the Fc gamma receptors (FcgRs) mainly expressed on natural killer (NK) cells and monocytes/macrophages, and leads to cell death via perforin/granzyme, TRAIL, and FasL. 27, 28 These ADCC processes are also suggested to affect adaptive tumor immunity by enhancing antigen presentation. 29, 30 Therefore, enhancement of ADCC is expected to be important in altering the tumor microenvironment. Afucosylation of the carbohydrate chain in human Fc has been reported to greatly enhance ADCC by increasing the binding affinity between Fc and FcgRIIIa.
human IgG1 to generate DS-8895a. Its binding to EPHA2 was confirmed by flow cytometric analysis using CT26.WT cells transiently transfected with wild-type or truncated mutants of human EPHA2 (Fig 1A) . Wild-type EPHA2 (amino acids 24-976) was recognized by the anti-EPHA2 mAb. In contrast, the truncated mutant that lacked amino acids 438-527 did not bind to the anti-EPHA2 mAb (Fig 1B) (Fig 1A) . 21, 22 DS-8895a bound to EPHA2DEN, the shortest form of truncated EPHA2 (Fig 1B) , suggesting that DS-8895a detects the juxtamembrane domain of EPHA2 and binds to both full-length and MT1-MMP cleaved, namely cancer-associated forms of EPHA2.
A Blast search against human proteins identified ones similar to the region containing the C-terminal FnIII domain of EPHA2. However, DS-8895a did not bind to those proteins (Fig. 2) . This result suggests that DS-8895a specifically binds to human EPHA2.
To examine the effects of DS-8895a on tyrosine phosphorylation of EPHA2, EPHA2-positive cancer cells (human triple negative breast cancer MDA-MB-231 cells and human gastric cancer 44As3 cells) were treated with DS-8895a in the presence and absence of an EPHA2 ligand, ephrin-A1. In the absence of ephrin-A1, DS-8895a treatment did not induce tyrosine phosphorylation of EPHA2 in both cell lines. In the presence of ephrin-A1, tyrosine phosphorylation of EPHA2 was observed in both cell lines, and DS-8895a partially inhibited the tyrosine phosphorylation at the highest concentration of 10 mg/mL ( Fig. 3A and 3B ). These results suggest that DS-8895a does not have EPHA2 agonistic activity, and has antagonistic activity. The arrows indicate sites of cleavage of EPHA2 by MT1-MMP. SP, signal peptide; FnIII, fibronectin type III domain; TM, transmembrane domain; Tyr kinase, tyrosine kinase domain; SAM, sterile a motif; FL, FLAG-tag; Lin, linker sequence; EPHA2wt, wild-type EPHA2 with aa 24-976; EPHA2DEN, EPHA2 lacking aa 29-437; EPHA2DFnIIIC, EPHA2 lacking aa 438-527. (B) Binding of DS-8895a to truncated mutants. CT26.WT cells were transfected with FLAG-tagged EPHA2wt, EPHA2DEN, and EPHA2DFnIIIC. DS-8895a binding and protein expression levels of transfected genes were evaluated by flow cytometry. Human IgG1 and rat IgG2a were used as isotype controls for DS-8895a and anti-FLAG antibody, respectively.
Afucosylated anti-human EPHA2 antibody with enhanced ADCC activity DS-8895a is humanized IgG1 that is afucosylated to enhance ADCC activity. To compare the ADCC activity of DS-8895a to that of its fucose-containing humanized parent antibody, ADCC assays were conducted using EPHA2-positive MDA-MB-231 cells as target cells and human peripheral blood mononuclear cells (PBMCs) as effector cells. DS-8895a showed markedly increased ADCC activity compared to its parent antibody in the assays using PBMCs from the 2 independent donors (Fig. 4) . The half-maximal effective concentration (EC 50 ) values for ADCC activity of DS-8895a were 8.6 and 57.1 ng/mL, where the EC 50 values of the parent antibody were 105.6 and 821.9 ng/mL in donor A and B, respectively (Fig. 4) .
Antitumor effects in a breast tumor model
We explored the antitumor activity of DS-8895a in xenograft models. Athymic nude mice were subcutaneously inoculated with EPHA2-positive MDA-MB-231 cells. Immunohistochemical analysis confirmed EPHA2 expression in the xenograft tumors (Fig. 5 ). In this model, DS-8895a inhibited tumor growth in a dose-dependent manner ( Fig. 6 , P < 0.0001), and the antitumor effect of DS-8895a was statistically significant (0.03 mg/kg: P D 0.0356, 0.1 mg/kg: P D 0.0086, 0.3, 1, and 3 mg/kg: P < 0.0001) when compared with the vehicle group. The result indicates that DS-8895a has potent antitumor activity in the breast cancer model.
Antitumor effects in a gastric tumor model
The antitumor activity of DS-8895a was further evaluated in another xenograft model. Athymic nude mice were subcutaneously inoculated with EPHA2-positive human gastric cancer SNU-16 cells. EPHA2 expression was also confirmed in the xenograft tumors (Fig. 5 ). In this model, DS-8895a also inhibited tumor growth in a dose-dependent manner ( Fig. 7A , P < 0.0001). The antitumor effect of DS-8895a at 10 mg/kg was statistically significant when compared with the vehicle group (P D 0.0006).
Combination with a chemotherapeutic agent
To evaluate combination with a chemotherapeutic agent in the gastric tumor model, the mice received DS-8895a or cisplatin (CDDP) monotherapy or a combination of both. CDDP alone did not inhibit SNU-16 tumor growth even at the doses of 5 and 10 mg/kg (Fig. 7B , P D 0.9109 and P D 0.2426, respectively). When a suboptimal dose of DS-8895a (5 mg/kg) was 
Discussion
EPHA2 is overexpressed in a wide range of cancers and is associated with poor prognosis. EPHA2 upregulation has also been reported in vemurafenib (a BRAF V600E inhibitor)-resistant cancer cells and is involved in the resistance. 33 In addition, truncated membrane-anchoring forms of EPHA2 promote oncogenic signaling. 21, 22 These findings indicate the importance of EPHA2 as a target for cancer therapy. We demonstrated that DS-8895a binds to the extracellular juxtamembrane region of EPHA2, as shown in Fig. 1 . This result suggests that DS-8895a can target the truncated forms as well as full-length EPHA2 and is effective even in MT1-MMP-positive tumors.
ADCC is mediated by FcgR-expressing NK cells or monocytes/macrophages and thought to be at least in part involved in the therapeutic effects of rituximab, trastuzumab, and cetuximab. 24 Recently, afucosylation of antibody by using a couple of technologies has been shown to increase ADCC. 34 Two afucosylated mAbs with enhanced ADCC have been approved: mogamulizumab, an afucosylated humanized anti-CCR4 mAb (using POTELLIGENT technology) for the treatment of adult T-cell leukemia-lymphoma, peripheral T-cell lymphoma, and cutaneous T-cell lymphoma; obinutuzumab, an afucosylated humanized anti-CD20 mAb (using GlycoMAb technology) for the treatment of chronic lymphocytic leukemia. 25, 26 We produced DS-8895a, an afucosylated anti-EPHA2 mAb to target EPHA2-expressing cancers. Afucosylated DS-8895a exhibited more potent ADCC than its fucose-containing parent antibody (Fig. 4 ). An afucosylated antibody is reported to induce potent ADCC activity even in the effector cells expressing low-affinity variants of FcgRIIIa (158 valine (V)/phenylalanine (F) or F/F). 35 Moreover, an afucosylated antibody overcomes inhibitory signals induced by the interaction of inhibitory killer cell immunoglobulin-like receptors (KIRs) on effector cells with human leukocyte antigens (HLAs) on target cells, whereas the fucose-containing antibody mediated ADCC is suppressed by them. 36 These evidences support that an afucosylated antibody potentially overcomes the inhibitory effects resulting from the genotypes in FcgRIIIa, KIR, and HLA.
We also demonstrated that DS-8895a significantly inhibited tumor growth in breast and gastric tumor mouse models ( Fig. 6 and Fig. 7 ). Immunohistochemistry for EPHA2 was performed using MDA-MB-231 and SNU-16 xenograft tumors (Fig. 5) . Expression levels of EPHA2 were higher in MDA-MB-231 tumors than in SNU-16 tumors. Consistent with the observations, DS-8895a showed stronger antitumor activity in MDA-MB-231 tumors than in SNU-16 tumors (Fig. 6 and Fig. 7) . Interestingly, MDA-MB-231 cells used for the studies harbor mutations in KRAS and BRAF. 19 These mutations are associated with aberrant cell signaling and resistance to a variety of therapies. 20 The result also suggests that DS-8895a is effective even in tumors with such mutations since ADCC activity is independent of the tumor signaling pathways.
A BLAST search identified human proteins similar to the region containing the C-terminal FnIII domain of EPHA2. DS-8895a did not bind to those proteins (Fig. 2) . This result suggests that DS-8895a specifically binds to EPHA2 and offtarget binding is unlikely. DS-8895a also did not bind to mouse EPHA2 (data not shown), suggesting that DS-8895a directly targets inoculated human cancer cells and does not affect mouse cells including EPHA2-expressing vascular endothelial cells in the xenograft models.
Combination of ADCC-mediating antibody with chemotherapeutic agents raises a concern regarding the possible effects of a chemotherapeutic agent on immune cells and the resultant ADCC activity. However, DS-8895a showed increased antitumor activity in the presence of CDDP, and the chemotherapeutic agent did not have a negative impact on the efficacy in the model tested. GA201, an afucosylated anti-EGFR mAb, also showed combination benefit with irinotecan in a mouse xenograft model. 37 These results suggest that ADCC-mediating antibody is potentially effective even in the presence of certain chemotherapeutic agents.
Recently, several studies have suggested that ADCC is associated with not only direct cell killing but also induction of adaptive immunity to cancer cells. In tumor-bearing mice, macrophagedependent ADCC by anti-CD20 mAb induced antitumor antigen-specific T cells through the uptake of antigen-antibody complexes by dendritic cells (DCs). 29 Another study showed that increased epidermal growth factor receptor (EGFR)-specific T cells were observed in cetuximab-treated patients with head and neck cancer in comparison to that in cetuximab-na€ ıve patients and that in vitro, cetuximab induced DC maturation in an NK cell-dependent manner and promoted cross-presentation by DC to T cells specific not only for EGFR but also for MAGE-3.
38
These data support the concept that ADCC-mediating mAbs can also induce T cell responses specific for tumor antigens. 29, 30 However, the activation and activity of tumor-specific T cells are often suppressed by immune checkpoint molecules such as CTLA-4 and PD-1. 39 Thus, ADCC-mediating mAbs may lead to more effective antitumor effects when combined with immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1, and anti-PD-L1 mAbs). Another approach to enhance the efficacy of ADCC- mediating mAbs is combination with an agonist for co-stimulatory molecules. In particular, anti-CD137 agonistic mAb enhanced rituximab-, trastuzumab-, and cetuximab-mediated ADCC and showed combination benefits with these ADCCmediating mAbs in tumor-bearing mice. [40] [41] [42] These combination approaches are expected to be more suitable for ADCC-enhancing mAbs such as DS-8895a than for fucose-containing ADCCmediating mAbs.
Taken together, the novel afucosylated anti-EPHA2 mAb, DS-8895a, showed increased in vitro ADCC activity and antitumor effects in mouse xenograft models. DS-8895a is expected to be effective for the treatment of patients with EPHA2-positive malignant tumors and is currently under clinical development.
Materials and methods

Antibodies
Mice were immunized with recombinant human EPHA2, and the obtained mouse anti-EPHA2 antibody was humanized as human IgG1. The obtained humanized antibody was afucosylated using POTELLIGENT technology from BioWa, Inc.
Cells
The human breast cancer cell line, MDA-MB-231, the human gastric cancer cell line, SNU-16, and the mouse colon carcinoma cell line CT26.WT were purchased from the American Type Culture Collection. The human gastric cancer cell line 44As3 was obtained from Yasuda Women's University. 43 MDA-MB-231 cells were cultured in Leibovitz's L-15 (Thermo Fisher Scientific) or RPMI1640 (Thermo Fisher Scientific) both supplemented with 10% heat-inactivated fetal bovine serum (FBS, Thermo Fisher Scientific) at 37 C in a humidified atmosphere without CO 2 (Leibovitz's L-15) or in a humidified atmosphere of 5% CO 2 (RPMI1640). SNU-16, CT26.WT, and 44As3 cells were cultured in RPMI1640 supplemented with 10% heatinactivated FBS at 37 C in a humidified atmosphere of 5% CO 2 . The 293F cells (Thermo Fisher Scientific, R790-07) were cultured in FreeStyle 293 Expression Medium (Thermo Fisher Scientific, 12338-018) at 37 C in a humidified atmosphere of 8% CO 2 with shaking at 135 rpm. Ã P < 0.05 as compared to the vehicle group (day 28, Student's t-test). yP < 0.05 as compared to the DS-8895a (5 mg/kg) monotherapy group (day 28, Dunnett's test).
x P < 0.01 as compared to the CDDP (10 mg/kg) monotherapy group (day 28, Student's t-test with Bonferroni correction). n D 9 per group.
Constructs
To construct a destination vector, Reading Frame Cassette B (RfB) of Gateway Vector Conversion System (Thermo Fisher Scientific) was ligated into blunt-ended HindIII and BglII sites of pFLAG-myc-CMV-19 (Sigma-Aldrich). The resultant vector was designated pFLAG-GW. 0 -GGGGACCACTTTGTACAAGAAAGCTGGGTCT CAGATGGGGATCCCCACAGTGTTC-3 0 . The underlines represent the coding regions of EPHA2, and the double underlines represent stop codons. The PCR fragments were cloned into pDONR221 (Thermo Fisher Scientific) by BP reactions and then transferred to pFLAG-GW by LR reactions. The resultant vectors were designated pFLAG-EPHA2wt, pFLAG-EPHA2DEN, and pFLAG-EPHA2DFnIIIC. A BLAST search (BLASTP 2.2.22C) 44 was performed to identify human proteins with high amino acid sequence similarity to the region containing the C-terminal FnIII domain of human EPHA2. To generate plasmids expressing the identified genes: EPHA3 isoform a (EPHA3a), EPHA5 isoform a (EPHA5a), EPHB3, EPHB4, PTPRS isoform 2 (PTPRS-2), PTPRS isoform 4 (PTPRS-4), and PTPRF isoform 2 (PTPRF-2), AttB sites were incorporated into the genes by PCR reactions using the following primers: EPHA3a forward, 5 0 -GGGGACAAGTTTGTACAAAAAAG-CAGGCTCAGAACTGATTCCGCAGCCT-3 0 ; EPHA3a reverse,
The underlines represent the coding regions of the genes, and the double underlines represent stop codons. The PCR fragments were cloned into pDONR221 by BP reactions and then transferred to pFLAG-GW by LR reactions. The resultant vectors were designated pFLAG-EPHA3a, pFLAG-EPHA5a, pFLAG-EPHB3, pFLAG-EPHB4, pFLAG-PTPRS-2, pFLAG-PTPRS-4, and pFLAG-PTPRF-2. Analysis of conserved domains was performed using the human EPHA2 sequence (GeneBank Accession Number NM_004431.3). The signal peptide cleavage site and the transmembrane domain of EPHA2 were predicted by SignalP v. 3.0 and TMHMM Server v. 2.0, respectively. 45, 46 The other conserved domains of EPHA2 were predicted by NCBI's CD-search. 47 Transfection, cell staining, and flow cytometry CT26.WT cells were transfected with pFLAG-EPHA2wt, pFLAG-EPHA2DEN, and pFLAG-EPHA2DFnIIIC by using Lipofectamine 2000 (Thermo Fisher Scientific). The transfected and non-transfected CT26.WT cells were stained with 5 mg/mL DS-8895a, 5 mg/mL human IgG1 (an isotype control for DS-8895a, Eureka Therapeutics, ET901), 1 mg/mL PE-labeled anti-FLAG mAb (Biolegend, 637309), or 1 mg/ mL PE-labeled rat IgG2a k (an isotype control for anti-FLAG mAb, Biolegend, 400507). The cells stained with DS8895a or human IgG1 were further stained with APC-labeled F(ab') 2 of goat anti-human IgG, Fcg fragment specific (Jackson ImmunoResearch, 109-136-170). To discriminate dead cells, the cells were stained using LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Thermo Fisher Scientific). and then fixed with BD FACS Lysing Solution (Becton, Dickinson and Company). 293F cells were transfected with pFLAGEPHA2wt, pFLAG-EPHA3a, pFLAG-EPHA5a, pFLAG-EPHB3, pFLAG-EPHB4, pFLAG-PTPRS-2, pFLAG-PTPRS-4, pFLAG-PTPRF-2, and pFLAG-GW using 293fectin reagent (Thermo Fisher Scientific, 12347019). pFLAG-GW was used as a negative (mock) control. Two days after the transfection, cells were stained with 10 mg/mL of DS-8895a, human IgG1 (an isotype control for DS-8895a, Enzo Life Sciences, ALX-804-133-C100), monoclonal ANTI-FLAG M2 antibody (anti-FLAG mAb, Sigma-Aldrich, F1804), or mouse IgG1 (an isotype control for anti-FLAG mAb, Becton, Dickinson and Company, 554721). Cells were then stained with fluorescein isothiocyanate (FITC)-conjugated anti-human IgG (Jackson ImmunoResearch Laboratories, 109-096-088) for DS-8895a and human IgG1 or FITC-conjugated anti-mouse IgG (MP Biomedicals, 55493) for anti-FLAG mAb and mouse IgG1 and then stained with 7-AAD (Thermo Fisher Scientific, A1310). The stained cells were analyzed on BD FACS Canto II (Becton, Dickinson and Company). Data analysis was performed using FlowJo version 7.6.5 (Tree Star, Inc.).
Western blotting and immunoprecipitation
MDA-MB-231 and 44As3 cells were seeded into 12-well plates and cultured overnight in Leibovitz's L-15 containing 10% heat inactivated FBS at 37 C in a humidified atmosphere without CO 2 and in RPMI1640 containing 10% heat inactivated FBS at 37 C in a humidified atmosphere of 5% CO 2 , respectively. The next day, culture media were removed, and cells were starved in Leibovitz's L-15 (MDA-MB-231) and RPMI1640 (44As3) both without FBS overnight. After removing the starvation media, cells were treated with DS-8895a and control human IgG1 (Enzo Life Sciences) at the concentrations shown in Fig C in a humidified atmosphere of 5% CO 2 for 16 hours. The final concentrations of each reagent are shown in Fig. 4 . Lysis of target cells was determined by evaluating lactate dehydrogenase (LDH) release (excitation/emission D 540/590 nm) using CytoTox-ONE reagent Homogeneous Membrane Integrity Assay (Promega). The percent specific LDH release was calculated using the following equation:
x is the fluorescence intensity of a test well, a is the mean fluorescence intensity under spontaneous release, and b is the mean fluorescence intensity under maximum release from Triton X-100-lysed target cells. The assay was conducted in triplicate.
EC 50 values of DS-8895a and its parent antibody were estimated according to the Sigmoid Emax model that is defined by the following equation.
[Sigmoid Emax model]
E 0 : response when dose is 0 (vehicle control, E 0 D 0) E max : mean maximal response (percent of specific LDH release at 10 mg/mL of antibodies).
Conc: concentration of DS-8895a or parent antibody (mg/mL) EC 50 : the concentration of DS-8895a or its parent antibody at which specific LDH release (%) was equal to (E 0 C E max )/2 (mg/mL) g: sigmoidicity factor EC 50 values (mg/mL) were rounded to 4 decimal places and expressed in ng/mL. Statistical analyses were performed using SAS System Release 8.2 (SAS Institute Inc.). The mice were randomized into the indicated number of groups on day 21 (for MDA-MB-231 tumors) or day 7 (for SUN-16 tumors) according to the estimated tumor volume. CDDP was purchased from Nippon Kayaku Co., Ltd. Mice received treatment as described in Figs. 6 and 7 from day 21 and day 7, respectively.
Mouse xenograft models
Immunohistochemistry (IHC)
Female nude mice bearing MDA-MB-231 and SNU-16 tumors were euthanized by cervical dislocation under anesthesia, and subcutaneous tumors were dissected. After dissection, tumor tissues were fixed with 10% neutral buffed formalin (Mildform Ò 10N, Wako Pure Chemicals, 133-10311) for 2 days, and processed for standard formalin-fixed paraffin-embedded sections. IHC was performed using Autostainer Link 48 (DAKO) and PT Link (DAKO) at room temperature, unless otherwise stated. All of the primary antibodies (Goat anti-EPHA2 Ab [R&D Systems, AF3035] and Normal goat IgG [R&D Systems, AB-108-C]) were diluted to a final concentration of 2.5 mg/mL with the DAKO REAL Antibody Diluent (DAKO, S2022). Approximately 4 mm thick sections were deparaffinized and pretreated with Envision FLEX TRS High (DAKO, K8004) for 40 min at 97 C followed by endogenous peroxidase blocking (DAKO, S2023) and protein blocking (DAKO, X0909). Then, the sections were sequentially incubated with the primary antibodies for 1 h, Histofine Simple Stain MAX-PO (Goat) (Nichirei Bioscience, 414161) as a secondary antibody for 30 min, and DABC Liquid (DAKO, K3468) for 10 min. Washes were performed after every step. Finally, the sections were counterstained with EnVision FLEX Hematoxylin (DAKO, K8008) for 5 min, and mounted. Two individual tumors from each xenograft model were used for IHC.
Statistical analysis
The dose-response relationship was evaluated by a Spearman's rank correlation coefficient hypothesis test (null hypothesis: correlation coefficient D 0). In the combination study with CDDP, statistical analysis was performed with Student's t-test (the vehicle group versus the DS-8895a monotherapy group), Dunnett's test (the vehicle group vs. the CDDP monotherapy groups, and the DS-8895a monotherapy group versus DS8895a and CDDP-treated groups), and Student's t-test with Bonferroni correction (each CDDP monotherapy group vs. each DS-8895a and CDDP-treated group). A P value of less than 0.05 (2-sided) was considered statistically significant. All the statistical analyses were performed using SAS System Release 8.2.
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